Germacrone reguates proliferation, migration and chemoresistance of thyroid cancer BCPAP cells through FOXO3-FOXM1 axis
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
Objective: To explore how germacrone regulates the proliferation, migration and chemoresistance of human thyroid cancer BCPAP cells and doxorubicin (DOX) resistant BCPAP cells (BCPAP/DOX) through the forkhead box O3 (FOXO3)-FOX subclass M1 transcription factor (FOXM1) signaling pathway. Methods: BCPAP cells were cultured routinely and used to construct BCPAP/DOX cells. MTT method was applied to detect the effects of different concentrations of germacrone on the proliferation of BCPAP and BCPAP/DOX cells. BCPAP and BCPAP/DOX cells were divided into control group (Ctrl), negative control group (NC, transfected with sh-NC plasmid), low concentration germacrone group (0.10 mmol/L), high concentration germacrone group (0.15 mmol/L), high concentration germacrone (0.15 mmol/L) + sh-FOXO3 group (transfected with sh-FOXO3 plasmid). The sh-NC plasmid and sh-FOXO3 plasmid were transfected into the corresponding BCPAP and BCPAP/DOX cells with transfection reagents. The proliferation and migration of the cells were detected using CCK-8 assay and scratching healing assay, and the expression of FOXO3, FOXM1, BAX, MMP-9 and multi-drug resistant-1 (MDR-1) was detected using WB assay. Results: The expression of FOXO3 was successfully knocked down in BCPAP and BCPAP/DOX cells. Both low and high concentrations of germacrone could significantly inhibit the proliferation and migration of BCPAP and BCPAP/DOX cells, reduce the protein expression of FOMX1, MMP-9 or MDR-1 (in BCPAP/ DOX cells), and increase the protein expression of FOXO3 and BAX (all P < 0.05). Notably, the effects were more significant with high concentration germacrone compared to that of low concentration (all P < 0.05). Knockdown of FOXO3 partially reversed the effects of germacrone on these cells (all P < 0.05). Conclusion: Germacrone may regulate the proliferation and migration of BCPAP and BCPAP/DOX cells and reduce chemotherapy resistance of BCPAP/DOX cells through the FOXO3/FOXM1 signaling pathway.